LITS

#4410
Lite Strategy, Inc. - Common Stock
0.9 9 USD
+0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
0.99
0.99
Jahresspanne
0.69
3.23
Tagesänderung
+1.02%
Monatliche Änderung
+2.06%
6 month change
-8.33%
Jahresänderung
-66.78%
Vorheriger Schlusskurs
0.9 8
Open
0.9 9
Tief
0.9 9
Hoch
0.9 9
Volumen
3
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Dividenden Documents

2026

Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Lite Strategy, Inc. current report, Q3 FY2026
8-K
Current report, Q2 FY2026
Lite Strategy, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q3 FY2026
Lite Strategy, Inc. quarterly report, Q3 FY2026
10-Q
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Lite Strategy, Inc. current report, Q1 FY2026
8-K

2025

Quarterly report, Q2 FY2025
Lite Strategy, Inc. quarterly report, Q2 FY2025
10-Q
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K
Current report, Q4 FY2025
Lite Strategy, Inc. current report, Q4 FY2025
8-K

Lite Strategy, Inc. current report, Q1 FY2025

Full document

Business Context and Reporting Period

This Form 8-K reports on the Annual Meeting of Stockholders held by MEI Pharma, Inc. on January 30, 2025. The filing details the results of three proposals submitted to security holders. Note: The request metadata references "Lite Strategy, Inc.," but the filing text explicitly identifies the registrant as MEI Pharma, Inc.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.

Material Changes and Voting Results

At the Annual Meeting, 4,299,938 shares were represented out of 6,662,857 shares outstanding. The following proposals were voted upon:

  • Proposal 1 (Election of Directors): Two nominees were elected to three-year terms expiring in 2028:
    • Mr. Frederick W. Driscoll: 2,360,948 For; 842,254 Withheld; 1,096,736 Broker Non-Votes.
    • Dr. Nicholas R. Glover: 2,722,093 For; 481,109 Withheld; 1,096,736 Broker Non-Votes.
  • Proposal 2 (Advisory Vote on Executive Compensation): Approved.
    • For: 2,127,143
    • Against: 456,162
    • Abstain: 619,897
    • Broker Non-Votes: 1,096,736
  • Proposal 3 (Ratification of Auditors): Ratified the appointment of Deloitte & Touche LLP for the fiscal year ending June 30, 2025.
    • For: 4,255,692
    • Against: 33,846
    • Abstain: 10,400

Guidance, Outlook, and Risks

The filing text does not provide a clear value for future guidance, management commentary on business outlook, specific risks, contingencies, or unusual items. The document is limited to the disclosure of voting outcomes.

Investor Verification Checklist

  • Verify the identity of the registrant (MEI Pharma, Inc.) against the metadata provided (Lite Strategy, Inc.).
  • Confirm the total number of shares outstanding (6,662,857) and the percentage of shares represented at the meeting (approximately 64.5%).
  • Review the definitive proxy statement referenced in the filing for detailed biographical information on the elected directors and executive compensation specifics.
  • Check subsequent filings for the official appointment of Deloitte & Touche LLP as the independent auditor.